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SUMMARY
Vancomycin has been documented to cause various adverse
cutaneous reactions. We present a case report of a man,
who developed a large localized erythematous plaque in his
forearm  following  parenteral  vancomycin  therapy.  We
believe this to be the first reported case of such cutaneous
reaction associated with parenteral vancomycin therapy. 
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CASE REPORT 
Approved by the United States Food and Drug Administration
(FDA) in 1958
1, vancomycin has been in clinical use for at
least  half  a  century.  It  is  an  antibiotic,  belonging  to  the
glycopeptide  group  with  good  bactericidal  activity  against
Gram  positive  bacteria.  The  use  of  vancomycin  has  seen
steady increase in recent years, largely due to the rise in the
incidence  of  Methicillin  Resistant  Staphylococcus  aureus
(MRSA) infections. Not surprisingly, with a more widespread
use, more vancomycin-related adverse reactions have been
reported. 
Among the various adverse cutaneous reactions attributed to
vancomycin, the Red Man’s Syndrome is probably one of the
most  well-known.  Non-immunologic,  direct  histamine
release drives the pathogenesis of this reaction and it usually
occurs in association with a rapid vancomycin infusion
2,3. 
Other  less  common  but  clinically  significant  cutaneous
manifestations  include  bullous  dermatosis,  vasculitis,  drug
rash  with  eosinophilia  and  systemic  symptoms  (DRESS),
Steven-Johnson  syndrome  (SJS)  and  toxic  epidermal
necrolysis (TEN).
Vancomycin has also been reported to cause phlebitis with
parenteral  therapy.  Given  the  acid  nature  of  vancomycin
with  its  low  pH,  this  effect  is  likely  secondary  to  a  direct
irritant effect exerted by vancomycin running through the
vasculature. In the extreme case, vancomycin can leak and
extravasate to cause skin necrosis
4. 
We would like to report a case of a localized erythematous
plaque associated with parenteral vancomycin therapy. 
A  82  year-old  Chinese  man  was  admitted  from  the
community  hospital  for  the  problem  of  nosocomial
pneumonia. He had just been discharged from the hospital a
week earlier for the treatment of his right foot gangrene. His
medical  history  was  significant  for  hypertension,
dyslipidaemia,  non-insulin  dependent  diabetes  mellitus
(NIDDM)  –  with  complications  of  nephropathy  and  severe
peripheral  vascular  disease  -  and  coronary  artery  disease
with coronary by-pass grafting (CABG) surgery in 2008. He
had no known drug allergies. 
He  had  developed  pneumonia  in  the  community  hospital
and was commenced on intravenous piperacillin-tazobactam
prior to his transfer to our hospital. As he was still febrile with
no clinical improvement despite the intravenous piperacillin-
tazobactam,  his  antibiotics  was  escalated  to  intravenous
imipenem (250 mg every 6 hourly – renal-adjusted dose) as
well as intravenous vancomycin.(1 g every morning – renal-
adjusted dose).  
On day 4 of antibiotics therapy, a large erythematous plaque
with  a  well-demarcated  border  developed  over  his  left
forearm (Figure 1). It was non-blanchable, non-pruritic, non-
tender and not warm to touch. This was not associated with
skin necrosis. The distal pulses were still well felt. The location
of the rash was just proximal to the intravenous cannula that
was infusing vancomycin. No rash was seen in other parts of
the body. 
The intravenous cannula was re-sited to another arm and the
speed  of  vancomycin  infusion  reduced  by  half.  The  rash
improved  clinically  without  any  active  intervention  and
resolved  almost  completely  by  day  11  of  intravenous
vancomycin therapy (Figure 2).
Given the locality of the rash, we postulate that the reaction
was likely a localized irritant effect of parenteral vancomycin
on the vascular bed leading to dermal edema, hence giving
rise to the localized erythematous plaque that we see. The
speed  of  the  infusion  had  probably  played  a  role  in
precipitating the rash. This was supported by the observation
that by changing the site of infusion to another arm and
slowing  down  the  rate  of  infusion,  a  similar  rash  did  not
develop in that particular arm.
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reported  case  of  such  cutaneous  reaction  associated  with
parenteral vancomycin. We hope that this case report will
create  awareness  among  clinicians  of  such  cutaneous
reaction to vancomycin in the future.
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Fig. 1 : A  large  erythematous  plaque  with  a  well-defined
border seen over the left forearm, involving close to its
entire  circumference.  The  arrow  indicates  the  site  of
previous intravenous cannula.
Fig. 2 : Significant improvement of the rash was seen after re-
siting  of  the  intravenous  cannula.  This  picture  was
taken on Day 11 of antibiotic treatment.
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